ERDF

Pixee Medical Accelerates Its Expansion in the US and Development of Its Next Generation of Innovative Products After $15M Fundraising

Retrieved on: 
Thursday, February 8, 2024
Biotechnology, Surgery, Medical Devices, Other Health, Health, FDA, AAOS, ERDF, Growth, Quality of life, MDR, Moscone Center, Shoulder, CE, Congress, Medicine, Elective surgery, Multimedia, Surgeon, Marketing, Patient, Artificial intelligence, European Regional Development Fund, Certification, Investment

This transaction, led by Relyens Innovation Santé, UI Investissement, Innovacom, Angelor and Bpifrance will enable Pixee Medical to accelerate its development in the United States and launch its next generation of innovative products.

Key Points: 
  • This transaction, led by Relyens Innovation Santé, UI Investissement, Innovacom, Angelor and Bpifrance will enable Pixee Medical to accelerate its development in the United States and launch its next generation of innovative products.
  • View the full release here: https://www.businesswire.com/news/home/20240208880497/en/
    The "OSER Bourgogne-Franche-Comté" financial instrument is financed by the Burgundy-Franche-Comté Region and the European Regional Development Fund (ERDF).
  • OSER Bourgogne-Franche-Comté facilitates access by small and medium-sized businesses to the financing they need for their development, to provide impetus to investment and modernization.
  • This investment is a significant step forward in our expansion in the US, which is a strategic market for our company.

EQS-News: Akribion Genomics receives the Hessian Founder Award for its innovative approach to a new cancer therapy

Retrieved on: 
Monday, December 25, 2023
Business idea, ERDF, European Regional Development Fund, Genome, Genomics, CRISPR, Quality of life, Cancer, BRAIN, Pharmaceutical industry, Vaccine, Economics

Zwingenberg, Germany, 20 November, 2023 – The Akribion Genomics team of BRAIN Biotech AG has received the Hessian Founder Award and was also named the winner in its category.

Key Points: 
  • Zwingenberg, Germany, 20 November, 2023 – The Akribion Genomics team of BRAIN Biotech AG has received the Hessian Founder Award and was also named the winner in its category.
  • Akribion Genomics was awarded in the "Innovative Business Idea" category for the discovery and development of an alternative CRISPR-Cas nuclease, which the start-up intends to develop into a new class of genetically based cancer therapies.
  • Better quality of life through more targeted therapies - this is what the about 20 scientists at Akribion Genomics hope to achieve with their programmable therapy platform.
  • The Hessian Founder Award, which is supported by European funding from the ERDF (European Regional Development Fund), does not award any prize money.

Hewlett Packard Enterprise Builds AI Supercomputer for CRIANN to Accelerate Scientific Research and Innovation

Retrieved on: 
Tuesday, October 17, 2023
Technology, Hardware, Artificial Intelligence, Data Management, Electroencephalography, European, Jean Zay, Adastra, Machine learning, Research, Private sector, European Regional Development Fund, AI, Grand, Jean-François Champollion, Carbon, Biotechnology, Climate, HPC, European High-Performance Computing Joint Undertaking, Health, Education, GENCI, HPE, DLC, Data analysis, 2004 Upper Normandy regional election, Cray, ERDF, Hewlett Packard Enterprise, Medical device, Austral

The new AI supercomputer is part of ongoing efforts to advance France’s national AI strategy and was co-funded by the Normandy Region, the French State, and the European Union through the European Regional Development Fund (ERDF).

Key Points: 
  • The new AI supercomputer is part of ongoing efforts to advance France’s national AI strategy and was co-funded by the Normandy Region, the French State, and the European Union through the European Regional Development Fund (ERDF).
  • Austral will help train robust AI models and run simulations and data analysis to accelerate scientific discovery and innovation in climate modeling, biotechnology, healthcare, and materials science, among other areas.
  • “We are proud to continue partnering with France’s national and regional centers to accelerate its AI missions by building powerful solutions using our supercomputers and AI software.
  • Accelerate innovation for autonomous driving by understanding obstacle avoidance across different environments, such as railways or adverse weather conditions.

PORTUGAL CERAMICS ATTENDS AIA CONFERENCE ON ARCHITECTURE IN SAN FRANCISCO

Retrieved on: 
Tuesday, June 6, 2023
Communication, Cinca, SIAC, ERDF, Perception, Multimedia, AIA, Competition (economics), Internationalization, Aleluia, Collection, Ceramic, Conference, Tile, Architecture

LSIBON, June 6, 2023 /PRNewswire/ -- PORTUGAL CERAMICS, a promotional brand developed by the Portuguese Association of Ceramics and Domestic Glass Industries (APICER) to promote the sector, will be attending the AIA Conference on Architecture, a prestigious global event in Architecture and Design held from 7-10 June in San Francisco, in the United States. Along with a stand designed by architect Luis Pedro Silva to represent the ceramic wall and floor tiles sub-sector, PORTUGAL CERAMICS will also organize a talk entitled "Portugal Ceramics Buildings Today". The speaker will be architect Luís Pedro Silva, designer of the emblematic work of the Porto Leixões Cruise Terminal, and the gathering will be held on 09 June at the PORTUGAL CERAMICS stand. The goal of attending this event is to promote Portuguese ceramics and its solutions, potential and benefits to international architects.

Key Points: 
  • A talk entitled "Portugal Ceramics Buildings Today" and a stand designed by architect Luís Pedro Silva promote the potential of Portuguese ceramics in this prestigious architecture and design conference.
  • LSIBON, June 6, 2023 /PRNewswire/ -- PORTUGAL CERAMICS , a promotional brand developed by the Portuguese Association of Ceramics and Domestic Glass Industries (APICER) to promote the sector, will be attending the AIA Conference on Architecture , a prestigious global event in Architecture and Design held from 7-10 June in San Francisco, in the United States.
  • Along with a stand designed by architect Luis Pedro Silva to represent the ceramic wall and floor tiles sub-sector, PORTUGAL CERAMICS will also organize a talk entitled "Portugal Ceramics Buildings Today".
  • The goal of attending this event is to promote Portuguese ceramics and its solutions, potential and benefits to international architects.

Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM•63: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes

Retrieved on: 
Monday, May 22, 2023
Health, Diabetes, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, BPI, Biochemistry, Obesity, Research and development, Development, Patient, Risk, European, AMF, Analysis, Phase, Volunteering, ERDF, European Regional Development Fund, Research, CHF, Partnership, Metabolism, BARD, Pharmacy, Trial of the century, Dysglycemia, Prediabetes, United Arab Emirates, Public Health Nutrition, Pharmaceutical industry, Medical device, Dietary supplement, Medical imaging, Cryptocurrency, ITT

We have provided unequivocal clinical evidence that TOTUM•63 is a promising solution for millions of people worldwide, helping to prevent the progression to type 2 diabetes.

Key Points: 
  • We have provided unequivocal clinical evidence that TOTUM•63 is a promising solution for millions of people worldwide, helping to prevent the progression to type 2 diabetes.
  • Beyond this great achievement, which opens up a new path, it is also a personal satisfaction, after almost 10 years of hard work."
  • This non-drug, plant-based active substance has the potential to significantly impact the management of early impairments of glucose metabolism."
  • The randomized and placebo-controlled REVERSE-IT Phase II/III study included 636 people with impaired glucose metabolism, ranging from prediabetes to untreated type 2 diabetes (early stage).

France: Power storage unit commissioned at the Plouguin wind farm

Retrieved on: 
Tuesday, May 2, 2023
ERDF, Aube, Electricity, European Regional Development Fund, Moulins, SMILE, BLX, Plouguin, Wind, European, TSX, Renewable energy, Boralex

The battery, which has a storage capacity of more than 3.3 MWh, is installed on the site of the Plouguin wind farm (Finistère, Brittany).

Key Points: 
  • The battery, which has a storage capacity of more than 3.3 MWh, is installed on the site of the Plouguin wind farm (Finistère, Brittany).
  • The Plouguin storage unit addresses three objectives: consolidating the stability of the French electricity grid, particularly in Brittany; supporting the deployment of high-capacity energy storage; and contributing to the integration of renewable energy into the electricity grid.
  • The Plouguin storage unit is a valuable addition to the adjacent wind farm.
  • Thanks to the Company’s persistent efforts to accelerate storage sites development, its storage project portfolio now stands at over 800 MW worldwide.

Lifespin Partners With Leipzig Research Center for Civilization Diseases (LIFE) to Explore Metabolic Correlations With Obesity and Diabetes

Retrieved on: 
Tuesday, April 25, 2023
Data Management, Technology, Diabetes, Health, General Health, Health Technology, Other Science, Research, Software, Artificial Intelligence, Science, Yale University, CT, Software as a service, Paulinum (University of Leipzig), Obesity, Partnership, Depression, University, European Social Fund Plus, Order of Merit of the Free State of Saxony, Workflow, NMR, ERDF, Stroke, Health status of Asian Americans, Metabolomics, Cancer, A.I, Ageing, Multimedia, Risk, Medicine, Inflammation, Biomarker, DSM-IV codes, Atherosclerosis, Free, Dementia, Cell biology, RUO, Metabolism, Patient, ESF, Nature, European, Artificial intelligence, Notifiable disease, Neurology, Saxons, Disease, Pharmaceutical industry, Medical imaging

The Leipzig Research Center for Civilization Diseases and Leipzig Medical Biobank have agreed to provide Lifespin with access to 8,000 patient samples from the LIFE Adult study, a long-term, population-based cohort study.

Key Points: 
  • The Leipzig Research Center for Civilization Diseases and Leipzig Medical Biobank have agreed to provide Lifespin with access to 8,000 patient samples from the LIFE Adult study, a long-term, population-based cohort study.
  • The metabolic profiles created by Lifespin will be returned to the Leipzig Research Center for Civilization Diseases, to be used to further expand the research database already established by LIFE.
  • “This important collaboration brings together the complementary, strong assets of both partners,” said Dr. Roland Geyer, COO of Lifespin GmbH.
  • Since then, LIFE has become an integral part of the research landscape at Leipzig University Medical Center and the University of Leipzig.

Valbiotis Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science

Retrieved on: 
Monday, March 13, 2023
Technology, Diabetes, Fitness & Nutrition, Biotechnology, Biometrics, Other Health, Food, Beverage, Health, Retail, Partner, Waist, European Regional Development Fund, Public Health Nutrition, DSM-IV codes, Database, PEA, Risk, ERDF, European, BPI, AMF, Research, Prediabetes, Patient, Hope, Human, Development, Collection, Phase, Good, Partnership, Research and development, Industrial Affairs Committee (Iceland), Dysglycemia, Pharmaceutical industry, Cryptocurrency

TOTUM•63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes.

Key Points: 
  • TOTUM•63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes.
  • Nestlé Health Science has the exclusive and global commercial rights to use TOTUM•63 in the prediabetes and type 2 diabetes market.
  • We also thank the Nestlé Health Science teams for their guidance and support as part of our strategic partnership on TOTUM•63.
  • In February 2020, Valbiotis signed a long-term global strategic partnership with Nestlé Health Science for the development and worldwide commercialization of TOTUM•63.

Block Makes First Social Impact Investment in the UK with ART Business Loans

Retrieved on: 
Thursday, March 2, 2023
Professional Services, Technology, Socially Responsible Investing, Finance, Software, Banking, NYSE, SME, Block, Poverty, European Regional Development Fund, Unity Trust Bank, TIDAL, History, Block, Inc., ERDF, Bank, ART, Investment, Square, TBD, Partnership, CDFI, Spiral

Block Inc (NYSE: SQ), a global technology company with a focus on financial services, is making its first social impact investment in the UK, providing £2m capital to ART Business Loans (ART), which is being matched by well-established ethical lender Unity Trust Bank.

Key Points: 
  • Block Inc (NYSE: SQ), a global technology company with a focus on financial services, is making its first social impact investment in the UK, providing £2m capital to ART Business Loans (ART), which is being matched by well-established ethical lender Unity Trust Bank.
  • ART, a Birmingham-based Community Development Finance Institution (CDFI), was founded in 1997 to help alleviate poverty through enterprise by facilitating loans for local businesses.
  • ART lends between £10,000 and £150,000 to businesses in underserved and disadvantaged communities which are unable to obtain their full requirements from traditional Banks.
  • Today’s investment comes from its $100m social impact investment fund, which was established in 2020 to support minority and underserved communities, allocating $10 million for social impact investments in markets outside the U.S.
    Amrita Ahuja, Chief Operating Officer and Chief Financial Officer at Block, said: “We are thrilled to be making our first UK social impact investment.

Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar

Retrieved on: 
Thursday, February 23, 2023
Research, Fitness & Nutrition, Cardiology, Other Natural Resources, Other Health, Biotechnology, Health, Natural Resources, Science, Other Science, Development, Research and development, European Regional Development Fund, LDL, Annual report, European, Letter, Risk, Shareholder, R, ERDF, Prediabetes, Acceleration, PEA, BPI, AMF, DSM-IV codes, Phase, CSR, Dietary supplement, Pharmaceutical industry, Security (finance), Rare-earth element, Cryptocurrency

Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, today publishes its 2023 Letter to Shareholders including its 2023 financial calendar.

Key Points: 
  • Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, today publishes its 2023 Letter to Shareholders including its 2023 financial calendar.
  • Valbiotis also announces its financial calendar for 2023:
    March 15: publication of the 2022 Annual Report;
    September 28: publication of the 2023 Half-Yearly Report.
  • Due to environmental considerations, as part of our commitments, our “Letter to Shareholders” will now be offered in digital format only: Letter to Shareholders No.6 .
  • Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time.